Resistance treatment for Relugolix

Relugolix was well tolerated by patients with prostate cancer, and most adverse events were consistent with physiological effects of testosterone suppression. In the HERO trial, 90.2% and 89.0% of patients in the repagliflox and leuprolide groups respectively completed 48 weeks of treatment; hot flashes were the most frequently reported adverse events in both groups; more than 10% of patients in either group experienced other adverse events, including fatigue, constipation, diarrhea, joint pain and hypertension. Most adverse events were grade 1 or 2 in severity.

Drug resistance often develops as tumor cells gradually adapt to the effects of the drug. By combining Repagliflozin with other medications, the effectiveness of treatment can be increased and the development of drug resistance can be reduced. This combination treatment may include the use of other targeted drugs, chemotherapy drugs, or immunotherapy. Each person may respond differently to medications, so an individualized treatment plan is important to manage resistance. Through genetic testing and biomarker analysis, an individual’s specific variations and biological characteristics can be identified, allowing for targeted treatment. Doctors may consider combinations of drugs, individualized treatment plans, breaks in treatment, and research into new drugs to increase the effectiveness of treatment and reduce the risk of drug resistance.

The original drug of Regogliflox has not yet been launched in the country, so it is not covered by medical insurance. There are European and Japanese versions of the original drug Rleglik available overseas. The ingredients of the two are basically the same. The price of the European version of 120mg*30 tablets per box may be around RMB 4,000, and the price of the Japanese version of 40mg*100 tablets per box may be around RMB 4,000 (the price may fluctuate due to exchange rates). Currently, there are no generic versions of Repagliflox produced and put on the market.